Company Description
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health.
The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.
It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult.
In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine.
It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates.
The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 65 |
| CEO | Dr. Shankar Musunuri M.B.A., Ph.D. |
Contact Details
Address: 11 Great Valley Parkway Malvern, Pennsylvania 19355 United States | |
| Phone | 484-328-4701 |
| Website | ocugen.com |
Stock Details
| Ticker Symbol | OCGN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001372299 |
| CUSIP Number | 67577C105 |
| ISIN Number | US67577C1053 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Shankar Musunuri M.B.A., Ph.D. | Co-Founder, Chief Executive Officer and Chairman |
| Dr. Uday B. Kompella Ph.D. | Co-founder and Independent Director |
| Michael Breininger CPA, M.B.A. | Interim Chief Accounting Officer and Principal Financial Officer and Corporate Controller |
| Dr. Arun Upadhyay Ph.D. | Chief Scientific Officer and Head of Research and Development |
| John Kouch J.D. | General Counsel |
| Tiffany J. Hamilton M.B.A. | Head of Corporate Communications |
| Dr. Durgaprasad Annavajjula Ph.D. | Vice President, Head of Program Management and Chief of Staff |
| Michael Shine M.B.A. | Senior Vice President of Commercial |
| Jyothy Pillai M.S. | Head of Regulatory and Quality |
| Dr. Huma Qamar CMI, M.D., M.P.H. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 18, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Apr 18, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 16, 2024 | 10-K | Annual Report |
| Apr 8, 2024 | 8-K | Current Report |
| Apr 2, 2024 | 8-K | Current Report |
| Apr 1, 2024 | 8-K | Current Report |
| Apr 1, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 21, 2024 | 8-K | Current Report |
| Mar 20, 2024 | 8-K | Current Report |
| Mar 18, 2024 | 8-K | Current Report |